Darwin AG
The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
Business. 7V0.DE is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm generates revenue through product sales and is listed on the Xetra exchange under the ticker 7V0.DE. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
7V0.DE is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm generates revenue through product sales and is listed on the Xetra exchange under the ticker 7V0.DE. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
The company maintains a strong liquidity position, with a current ratio of 4.05 and cash and equivalents amounting to 20.66 million EUR. The low debt-to-equity ratio of 0.03 indicates a conservative capital structure, and the market price of 6.55 EUR suggests a relatively low valuation compared to book value. The price-to-earnings ratio of 4.34 and price-to-book ratio of 0.74 further support this assessment.
Profitability metrics show a return on equity of 17.1% and a return on assets of 11.83%, which are strong indicators of efficient asset utilization and profitability. The operating income of 18.19 million EUR and net income of 18.10 million EUR reflect a healthy margin, although the gross profit of 10.33 million EUR suggests that cost management could be an area for improvement.
The company's revenue is concentrated in a single segment, with no disclosed geographic diversification. This lack of diversification could pose a risk if the primary market experiences economic downturns or regulatory changes. The company's revenue of 25.29 million EUR is derived from its core diagnostic products and services, with no significant diversification across product lines or customer bases.
The company's growth trajectory is positive, with a strong net income and operating income. The free cash flow of 16.90 million EUR indicates the company's ability to fund operations and potentially invest in growth opportunities. The capital expenditure of -4.34 million EUR suggests that the company is not heavily investing in new projects, which could limit future growth.
The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's low debt levels and strong cash position reduce the likelihood of liquidity issues. The dilution risk is also low, as there are no signs of imminent share issuance or dilution.
Recent events, including analyst estimates, show a strong buy recommendation with a mean price target of 26.00 EUR. The high price target of 30.00 EUR and low price target of 22.00 EUR indicate a wide range of analyst expectations, but the overall sentiment is positive.
- The company has a strong liquidity position with a current ratio of 4.05 and significant cash reserves.
- Profitability is robust, with a return on equity of 17.1% and a return on assets of 11.83%.
- The company's revenue is concentrated in a single segment, which could pose a risk if the primary market experiences downturns.
- Analysts have a positive outlook, with a mean price target of 26.00 EUR and a strong buy recommendation.
- The company's low debt-to-equity ratio and strong cash position reduce liquidity and dilution risks.
- "margin_outlook_rationale": "The company's strong operating and net income margins suggest a positive margin outlook driven by efficient cost management.",
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- 7V0.DE Market data — financials · 2026-05-27
- Darwin AG Market data — analyst estimates · 2026-05-27